LAS VEGAS, NV, UNITED STATES, January 15, 2025 /EINPresswire / -- The Alopecia Areata market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period.

Pfizer’s JAK/TEC inhibitor Litfulo has been recommended for NHS use as a treatment for hair loss caused by severe alopecia areata, the first drug therapy for a condition that affects around ...

The Alopecia Areata market report covers emerging drugs, current treatment practices ... Eli Lilly and Company/Incyte Corporation, Pfizer, Legacy Healthcare, Pfizer, Q32 Bio Inc., AbbVie, Amgen ...

The Alopecia Areata market report covers emerging drugs, current treatment practices ... Key Alopecia Areata Companies: Eli Lilly and Company/Incyte Corporation, Pfizer, Legacy Healthcare, Pfizer, Q32 ...

Pfizer said that Litfulo (ritlecitinib) is the first alopecia areata therapy to be cleared for use in adolescents in the EU. JAK1/2 inhibitor Olumiant (baricitinib) was the first drug to be ...

Ritlecitinib is under clinical development by Pfizer and currently in Phase II for Keloids ... Litfulo is indicated for the treatment of Alopecia areata for adults and children aged 12 years or older, ...

Financial writer analysis of Arcutis Biotherapeutics, Inc. stock surge and potential growth, FDA approvals, and partnerships in 2025. Click for this ARQT update.